Applied Materials Earns Intel’s 2024 EPIC Distinguished Supplier Award
SANTA CLARA, Calif., March 28, 2024 (GLOBE NEWSWIRE) — Applied Materials, Inc. today announced that it has earned Intel’s EPIC […]
IZEA Report Finds 40% of 18-to-29-Year-Olds Turn to TikTok for Product Research Before Making Big Purchases
ORLANDO, Fla., March 28, 2024 (GLOBE NEWSWIRE) — IZEA Worldwide, Inc. (NASDAQ: IZEA), the premier provider of technology, data, and […]
Performance Shipping Inc. Announces Filing of 2023 Annual Report on Form 20-F
ATHENS, Greece, March 28, 2024 (GLOBE NEWSWIRE) — Performance Shipping Inc. (NASDAQ: PSHG), (“we” or the “Company”), a global shipping […]
First Bank Announces First Quarter 2024 Earnings Conference Call
HAMILTON, N.J., March 28, 2024 (GLOBE NEWSWIRE) — First Bank (Nasdaq Global Market: FRBA) invites participation in a conference call […]
German American names Mary Moorhouse Chief Risk Officer
JASPER, Ind., March 28, 2024 (GLOBE NEWSWIRE) — German American Bancorp, Inc. (Nasdaq: GABC) announced today that Mary Moorhouse has […]
Highest Performances Announces Acquisition of an AI Humanoid Robot Hardware Manufacturer
GUANGZHOU, China, March 28, 2024 (GLOBE NEWSWIRE) — Highest Performances Holdings Inc. (NASDAQ: HPH) (“HPH” or the “Company”), a leading […]
Tonix Pharmaceuticals Announces Pricing of $4.4 Million Registered Direct Offering
CHATHAM, N.J., March 28, 2024 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a biopharmaceutical […]
FibroBiologics Files Patent Application Covering Fibroblast-based Technology for the Potential Treatment of Lupus
HOUSTON, March 28, 2024 (GLOBE NEWSWIRE) — FibroBiologics (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and […]
Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting
CAPE CANAVERAL, Fla., March 28, 2024 (GLOBE NEWSWIRE) — Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of […]
Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update
Advanced OTX-2002 in MYCHELANGELO™ I trial; initial cohorts demonstrated encouraging disease control rate in late-stage HCC patients Established a research […]
